title: The type of collagen cross-link determines the reversibility of experimental skin fibrosis.
abstract: Fibrotic processes in humans are characterised by an excessive accumulation of collagen containing increased levels of hydroxyallysine-derived cross-links. The occurrence of these cross-links appears to be an important criterion in assessing the irreversibility of fibrosis. We hypothesise that increased hydroxyallysine cross-linking results in a collagenous matrix that is less susceptible to proteolytic degradation and therefore the collagen deposition is no longer reversible. In this report, we show that collagen matrices with increased hydroxyallysine cross-link levels were less susceptible to matrix metalloproteinase 1 degradation than are collagen matrices containing low hydroxyallysine levels. These data indicate that the type of collagen cross-link influences collagen catabolism. In vivo evidence for the importance of the cross-linking type in determining the reversibility of the fibrotic process was found using the bleomycin-induced skin fibrosis mouse model. The analysis of the accumulated collagen in the fibrotic skin of bleomycin-treated mice did not reveal an increase in hydroxyallysine cross-link levels. In concurrence with our hypothesis, the collagen accumulation resolved in time when the mice were no longer receiving bleomycin treatment, showing the reversibility of the fibrosis. In conclusion, our data indicate that the type of collagen cross-linking is an important factor in determining whether the outcome of the fibrotic process is reversible or not.
authors.affiliation: TNO Quality of Life, Department of Biomedical Research, P.O. Box 2215, 2301 CE Leiden, The Netherlands.
authors.forename: Annemarie J
authors.initials: AJ
authors.lastname: van der Slot-Verhoeven
authors.forename: Ernst A
authors.initials: EA
authors.lastname: van Dura
authors.forename: Joline
authors.initials: J
authors.lastname: Attema
authors.forename: Bep
authors.initials: B
authors.lastname: Blauw
authors.forename: Jeroen
authors.initials: J
authors.lastname: Degroot
authors.forename: Tom W J
authors.initials: TW
authors.lastname: Huizinga
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Zuurmond
authors.forename: Ruud A
authors.initials: RA
authors.lastname: Bank
mesh_terms: D015074:2-Aminoadipic Acid / Q000031:analogs & derivatives* / Q000737:chemistry*; D000818:Animals; D001761:Bleomycin / Q000633:toxicity; D003094:Collagen / Q000737:chemistry* / Q000378:metabolism*; D005260:Female; D005355:Fibrosis / Q000139:chemically induced / Q000378:metabolism; D006801:Humans; D020781:Matrix Metalloproteinase 1 / Q000737:chemistry; D051379:Mice; D012867:Skin / Q000378:metabolism* / Q000473:pathology*
chemical_list: D001761:Bleomycin; D015074:2-Aminoadipic Acid; C042487:hydroxyallysine; D003094:Collagen; D020781:Matrix Metalloproteinase 1